Evidence map›Paper›PMID 42599692›Full record

ArticleActa crystallographica. Section D, Structural biology2026

Structural basis for T-cell receptor recognition of p53

Zhihui Duan, Jianfeng Zhao, Junping Wu, Yue Zhang, Ping Yuan, Yayun Zeng, Huimin Jin, Roy A Mariuzza, Daichao Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhihui DuanLaboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, People's Republic of China.
Jianfeng ZhaoInstitute of Neuroscience, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China.
Junping WuLaboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, People's Republic of China.
Yue ZhangLaboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, People's Republic of China.
Ping YuanLaboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, People's Republic of China.
Yayun ZengLaboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, People's Republic of China.
Huimin JinLaboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, People's Republic of China.
Roy A MariuzzaUniversity of Maryland Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA.
Daichao WuLaboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, People's Republic of China.

Funding

Structure and Activation of a Multiprotein Signaling ComplexR01AI129893 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI MARIUZZA, ROY A, ORBAN, JOHN · 2017 to 2021
$3.5M
Education Department of Hunan Province, Scientific Research Foundation of Hunan Provincial Education Department 24A0295Education Department of Hunan Province, Scientific Research Foundation of Hunan Provincial Education Department 24B0409National Natural Science Foundation of China 32100985National Natural Science Foundation of China 32270995Natural Science Foundation of Hunan Province 2023JJ10034NIAID NIH HHS R01 AI129893NIH HHS AI129893
6 · The paper itself

Abstract

Adoptive cell therapy (ACT) with tumor-specific T cells can mediate durable cancer regression. The main target of tumor-specific T cells are neoantigens resulting from mutations in self-antigens over the course of malignant transformation. To understand T-cell recognition of cancer neoantigens at the atomic level, we studied a T-cell receptor (TCR 4414A) that recognizes a neoepitope arising from a driver mutation in the p53 oncogene (p53

Indexed as

Antigens, NeoplasmHLA-A2 AntigenReceptors, Antigen, T-CellTumor Suppressor Protein p53Crystallography, X-RayHumansModels, MolecularMutationProtein ConformationAntigens, NeoplasmHLA-A2 AntigenReceptors, Antigen, T-CellTP53 protein, humanTumor Suppressor Protein p53cancer neoantigensMHCp53T-cell receptorsX-ray crystallography

Identifiers

PMID42599692
PMCPMC13532693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.